TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023
May 03 2023 - 4:02PM
TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage
biopharmaceutical company utilizing a cost-efficient,
CRO-independent product development platform to advance its
pipeline of novel targeted cancer therapeutics and to partner with
other life science companies, announced today that it will report
its first quarter 2023 financial and operating results after the
close of U.S. financial markets on Wednesday, May 10, 2023. In
addition, management will host a conference call to provide an
update on corporate activities and discuss the financial results.
Date: |
May 10, 2023 |
Time: |
4:30 pm Eastern Time (1:30 pm Pacific Time) |
Conference Call: |
In order to participate in the live conference call, you must
register in advance here: registration link. After registering, you
will receive an email with dial-in details and a unique conference
call access code required to join the live call. To ensure you are
connected prior to the beginning of the call, the Company suggests
registering a minimum of 10 minutes before the start of the call.
For those not planning to ask a question of management, the Company
recommends listening via the webcast. |
Webcast: |
https://traconpharma.gcs-web.com/events-and-presentations/upcoming-events |
A replay of the webcast will be available for 60
days on the website.
About TRACON
TRACON is a clinical-stage biopharmaceutical
company utilizing a cost-efficient, CRO-independent, product
development platform to advance its pipeline of novel targeted
cancer therapeutics and to partner with other life science
companies. The Company’s clinical-stage pipeline includes:
Envafolimab, a PD-L1 single-domain antibody given by rapid
subcutaneous injection that is being studied in the pivotal
ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4
antibody in Phase 1 development; and TRC102, a Phase 2 small
molecule drug candidate for the treatment of lung cancer. TRACON is
actively seeking additional corporate partnerships through a
profit-share or revenue-share partnership, or through franchising
TRACON’s product development platform. TRACON believes it can serve
as a solution for companies without clinical and commercial
capabilities in the United States or who wish to become
CRO-independent. To learn more about TRACON and its
product pipeline, visit TRACON’s website at
www.traconpharma.com.
Company Contact: |
Investor Contact: |
Charles Theuer |
Brian Ritchie |
Chief Executive Officer |
LifeSci Advisors LLC |
(858) 550-0780 |
(212) 915-2578 |
ctheuer@traconpharma.com |
|
TRACON Pharmaceuticals (NASDAQ:TCON)
Historical Stock Chart
From Apr 2024 to May 2024
TRACON Pharmaceuticals (NASDAQ:TCON)
Historical Stock Chart
From May 2023 to May 2024